Dissertations / Theses on the topic 'PHARMA] Life Sciences'

The objectives of this study are: (1) To compare the effectiveness of two dosing schedules of hepatitis B vaccine in achieving compliance within the vaccines; (2) To determine the immunization requirements in U.S. pharmacy schools both at admission and before the students begin clinical clerkships; and, (3) To design an immunization program for pharmacy students at the University of the Pacific in an attempt to enhance compliance.

Tic-like movements in rodents bear close similarities to those observed in humans both pharmacologically and morphologically. Pharmacologically, tics are modulated by serotonergic and dopaminergic systems and abnormalities of these systems have been reported in Tourette's Syndrome (TS). Therefore, serotonergic and dopaminergic modulation of tics induced by a thyrotrophin-releasing hormone (TRH) analogue were studied as possible models for TS. The TRH analogue MK771 induced a variety of tic like movements in mice; blinking fore-paw-licking and fore-paw-tremor were quantified and serotonergic and dopaminergic modulation was investigated. The selective dopamine D1 receptor antagonists SCH23390 and SCH39166 and dopamine D2 antagonists raclopride and sulpiride had no effect on MK771 induced blinking. The D1 antagonists attenuated fore-paw-tremor and -licking while the D2 antagonists were generally without effect on these behaviours. Ketanserin (5-HT2A/ alpha-1 antagonist) and ritanserin (5-HT2A/2C antagonist) were able to attenuate MK771-induced blinking and ketanserin, mianserin (5-HT2A/2C antagonist) and prazosin (alpha-1 adrenoceptor antagonist) were able to attenuate MK771-induced fore-paw-tremor and -licking. The 5-HT2C/2B antagonist SB200646A was without effect on blinking and fore-paw-licking but dose-dependently potentiated fore-paw-tremor. The 5-HT1A agonists 8-OH DPAT and buspirone attenuated blinking at the lower doses tested but were ineffective at the higher doses; the converse was found for fore-paw-licking and -tremor behaviours.

To offer an insight into the themes which will be explored at the Masterclass, in this short video Dr. McKenzie Calhoun and colleagues at the ETSU Family Physicians in Kingsport, Tennessee discuss how a model of interprofessional collaboration is typically applied and put into practice in the care of patients at the center. They highlight the importance and value of a team-based approach in enhancing the provision of primary healthcare.

Current anticoagulants carry a serious risk of bleeding complications. In addition, narrow therapeutic index, drug interactions, immunological reactions, toxicity and high cost to benefit ratio limits the effective use of these drugs in patients with thrombotic conditions.Heparin is the most widely used anticoagulant. We hypothesized that one of the major drawback of heparins, its non-specific interaction with the plasma proteins arises as a result of negative charges. To reduce these non-specific interactions, our laboratory designed sulfated low molecular weight lignin (LMWL) like biomacromolecules, which were found to be direct inhibitors of thrombin and factor Xa, acting through a unique exosite-2 mediated process. To elucidate the structural basis of this mechanism, we studied unsulfated and size fractionated LMWLs. Detailed enzyme inhibition studies with sulfated and unsulfated LMWLs of ferulic and caffeic acid oligomers revealed that sulfation was not absolutely critical for dual inhibition property and smaller oligomers can yield a potent anticoagulant. Mechanistically, unsulfated LMWLs retained exosite-2 mediated inhibition mechanism. A major advantage expected of the unsulfated LMWLs is the possibility that orally bioavailable anticoagulants may become possible.To identify target specific structures within the heterogeneous population of sulfated LMWLs, we prepared sulfated β-O-4-linked oligomer using chemical synthesis. Enzyme inhibition studies revealed that the sulfated β-O-4 LMWL were highly selective direct inhibitors of thrombin. These results show for the first time that specific structural features on LMWL scaffold dictate inhibition specificity. Studies in plasma and blood display highly promising anticoagulant profile for further studies in animals. To further study the LMWL scaffold as macromolecular mimetic of heparin; we investigated their effect in preventing cellular infection by herpes simplex virus-1 (HSV-1). Based on previous findings on sulfated lignins a size-dependent study on unsulfated LMWLs was done. The unsulfated lignins were found to not only inhibit HSV-1 entry into mammalian cells, but were more potent than sulfated lignins. Interestingly, shorter chains were found to be as active as the longer ones, suggesting that structural features, in addition to carboxylate groups, may be important. It can be expected that unsulfated lignins also antagonize the entry of other enveloped viruses, like HIV-1 and HCV that utilize heparan sulfate to gain entry into cells. The results further present major opportunities for developing lignin-based antiviral formulations for topical use.

Protein therapeutics are available as cytokines, clotting factors, enzymes, hormones, growth factors, antibodies et al. They have been shown to be effective in treating a variety of important human diseases. Since human insulin was approved as the first recombinant protein therapeutic, this field has experienced rapid growth. One of the biggest challenges for protein therapeutics in clinical application is their short half-life. Except for monoclonal antibodies, which have serum half-life for weeks, most of the protein therapeutics have half-lives ranging from minutes to hours. Kidney filtration, proteasome degradation and liver metabolism are the main factors that attribute to their short half-lives. The short half-life of protein therapeutics requires a higher dose or frequent application to maintain therapeutic concentration over a certain period. However, higher dose is easy to cause large plasma concentration fluctuation, which is easy to cause side effects. Most of protein therapeutics are not orally bioavailable. Frequent application will increase the burden of patients, affect their life quality, and reduce patient compliance. Thus, it is important to generate long-lasting therapeutics with improved pharmacokinetic properties. The current half-life extension approaches for protein therapeutics include PEGylation, albumin fusion or binding and fusion to an immunoglobulin Fc region. Their primary aim is to increase the size of biotherapeutics or to implement recycling by the neonatal Fc receptor (FcRn). However, the half-life extension by PEGylation, albumin fusion or Fc fusion is at the cost of binding affinity reduction. And the increase of size has limited their application in the field of anticancer agents where tumor penetration is required. Noncovalent albumin binding using albumin binding ligands such as fatty acids could maintain the small size and binding affinity. However, it would increase hydrophobicity, therefore is not suitable for protein therapeutics with low solubility. Here, we present a new approach for half-life extension for biotherapeutics. Human interleukin 2 (IL-2), a low solubility cytokine, was used as a model protein. By conjugating IL-2 with a hydrophilic small molecule that binds reversibly to the serum protein transthyretin, we enhanced its circulation half-life in rodents while maintained its in vitro bioactivity. To the best of our knowledge, this is the first demonstration of a successful approach that harnesses a small molecule in extending the circulation half-life of a protein while at the same time maintains the small size and hydrophilicity.

Aims The method for the confirmation of drugs of abuse for addiction testing within King’s College Hospital prior to 2008 was a labour intensive thin layer chromatography method. To replace this with a faster method more suited to future requirements, the laboratory bought a liquid chromatography system with ion trap mass spectrometric detection. The development of the routine analytical method and the implementation of this method within the laboratory using on-line solid phase extraction and Turboflow® sample preparation will allow the laboratory to operate successfully in the field of clinical drugs of abuse testing in the future. Method Analyses are performed on an ion trap mass spectrometer with an electrospray ion source following reversed phase liquid chromatography, initially using on-line solid phase extraction with a Jasco XLC® series autosampler and pump and later a Thermo Turboflow® on-line extraction method with a CTC Combi-Pal® autosampler and Agilent 1100 series liquid chromatography system. Elution of drugs and metabolites is performed with a multi-step gradient of ammonium formate buffer and acetonitrile, followed by regeneration of the extraction and analytical columns to starting conditions. Detection is achieved with a Thermo LCQ Fleet ion trap mass spectrometer with a combination of full spectrum survey scans, dedicated product ion scans, neutral loss scans and data dependent product ion scans in two analysis segments. Total run time is only 20 minutes, allowing a throughput of around 65 samples per day. Results The methods include the novel combination of the elimination of any hydrolysis step, on-line SPE or Turboflow extraction, detection of multiple drug groups, full spectrum analysis and library matching, the use of data dependent scans and ion trap mass spectrometry using MS3 and neutral loss scans. The methods developed were validated using a departmental method validation protocol and accepted for routine use. Simultaneous detection of over fifty analytes has been found possible in a range of clinically relevant drug groups, including opiates, amphetamines, methadone, propoxyphene, cocaine, ketamine and their metabolites. The use of neutral loss scans and product ion scans of phase 2 drug metabolites permits the addition of previously unidentified drugs and metabolites to the method, allowing the laboratory’s services to develop in line with requirements of the service. Quality is maintained through the use of standard operating procedures, staff training, quality control samples and external quality assessment. Conclusion Drugs of abuse testing is key for treatment and monitoring of drug addiction. The introduction of modern mass spectrometry techniques has reduced the turnaround time of routine analysis for a range of drugs and metabolites and increased the range of drugs that can be analysed. The methods introduced have revolutionised testing at King’s College Hospital and produced a method which is capable of evolving with the needs of the service to keep abreast of future requirements of the service.

Thesis (Ph. D.)--Ohio State University, 2004.
Title from first page of PDF file. Document formatted into pages; contains xiii, 154 p.; also includes graphics (some col.). Includes abstract and vita. Advisor: Sheryl L. Szeinbach, College of Pharamcy. Includes bibliographical references (p. 139-154).

The misassembly of soluble proteins into toxic aggregates, including amyloid fibrils, underlies a large number of human degenerative diseases. Cardiac amyloidoses, which are most commonly caused by aggregation of Immunoglobulin (Ig) light chains or transthyretin (TTR) in the cardiac interstitium and conducting system, represent an important and often underdiagnosed cause of heart failure. Two types of TTR-associated amyloid cardiomyopathies are clinically important. The Val122Ile (V122I) mutation, which alters the kinetic stability of TTR and affects 3% to 4% of African Americans, can lead to development of familial amyloid cardiomyopathy. In addition, aggregation of WT TTR in individuals older than age 65 years causes senile systemic amyloidosis. TTR-mediated amyloid cardiomyopathies are chronic and progressive conditions that lead to arrhythmias, biventricular heart failure, and death. As no Food and Drug Administration-approved drugs are currently available for treatment of these diseases, the development of therapeutic agents that prevent TTR-mediated cardiotoxicity is desired. Here, we report the characterization of AG10 , a potent and selective kinetic stabilizer of TTR. AG10 prevents dissociation of V122I-TTR in serum samples obtained from patients with familial amyloid cardiomyopathy. In contrast to other TTR stabilizers currently in clinical trials, AG10 stabilizes V122I- and WT-TTR equally well and also exceeds their efficacy to stabilize WT and mutant TTR in whole serum. Crystallographic studies of AG10 bound to V122I-TTR give valuable insights into how AG10 achieves such effective kinetic stabilization of TTR, which will also aid in designing better TTR stabilizers. The oral bioavailability of AG10 , combined with additional desirable drug-like features, makes it a very promising candidate to treat TTR amyloid cardiomyopathy. The second part of the thesis discusses harnessing TTR as a platform to enhance in vivo half-life of therapeutic peptides. The tremendous therapeutic potential of peptides has not yet been realized, mainly owing to their short in vivo half-life. Although conjugation to macromolecules has been a mainstay approach for enhancing protein half-life, the steric hindrance of macromolecules often harms the binding of peptides to target receptors, compromising the in vivo efficacy. Here we report a new strategy for enhancing the in vivo half-life of a model peptide Gonadotropin Releasing Hormone (GnRH) and its analog GnRH-A without compromising their potency. Apart from GnRH, we have used other peptides to study their proteolytic stability in vitro . Our approach involves endowing peptides with a small molecule that binds reversibly to the serum protein transthyretin. Although there are a few molecules that bind albumin reversibly, we are unaware of designed small molecules that reversibly bind other serum proteins and are used for half-life extension in vivo . We show here that our strategy was effective in enhancing the half-life of an agonist for GnRH receptor while maintaining its binding affinity, which was translated into superior in vivo efficacy.

The misassembly of soluble proteins into toxic aggregates, including amyloid fibrils, underlies a large number of human degenerative diseases. Cardiac amyloidosis, which is most commonly, caused by aggregation of Immunoglobulin (Ig) light chains or transthyretin (TTR) in the cardiac muscle, represent an important and often underdiagnosed cause of heart failure. TTR-mediated amyloid cardiomyopathies are chronic and progressive conditions that lead to arrhythmias, biventricular heart failure, and death. As no Food and Drug Administration-approved drugs are currently available for treatment of these diseases, the development of therapeutic agents that prevent TTR-mediated cardiotoxicity is desired. AG10 is a potent and selective kinetic stabilizer of TTR. AG10 prevents dissociation of TTR in serum samples obtained from patients with amyloid cardiomyopathy. The oral bioavailability and selectivity of AG10, makes it a very promising candidate to treat TTR amyloid cardiomyopathy. Understanding the reason behind the potency of AG10 would be beneficial for designing stabilizers for other amyloid diseases. This would be possible by designing and synthesizing structural analogues of AG10. Here we report the synthesis, characterization and analysis of AG10 analogs and the comparison of the in vitro activities of the synthesized analogs. The tremendous therapeutic potential of peptides has not been fulfilled and potential peptide therapies that have failed far outnumber the successes so far. A major challenge impeding the more widespread use of peptides as therapeutics is their poor pharmacokinetic profile, due to short In vivo half-life resulting from inactivation by serum proteases and rapid elimination by kidneys. Extending the In vivo half-life of peptides is clearly desirable in order for their therapeutic potential to be realized, without the need for high doses and/or frequent administration. Covalent conjugation of peptides to macromolecules (e.g. polyethylene glycol or serum proteins such albumin) has been the mainstay approach for enhancing the In vivo half-life of peptides. However, the steric hindrance and immunogenicity of these large macromolecules often compromises the In vivo efficacy of the peptides. Recently, our laboratory established the first successful reversible method of extending the half-life of peptides using serum protein TTR. The approach involved the use of a TTR Ligand for Half-life Extension (TLHE-1) which binds to TTR with high specificity and affinity. We have shown that our technology extends the half-life of multiple peptides without seriously affecting their activity. Our main objective here is to modify the structure of TLHE1 using linkers with different length and composition to optimize its affinity and selectivity for TTR in human serum.

Porcine buccal mucosa has been extensively used as in vitro model to study the permeability of drugs and assess their potential to deliver through buccal route. Porcine buccal mucosa is found to be very similar to human oral mucosa in structure and function. However, the in vitro permeation studies across porcine buccal mucosa show high variability which is mostly due to the various experimental and biological variables that are often overlooked while conducting such studies. The precise nature of the permeability barrier offered by the various tissue layers of buccal mucosa was investigated in this study. It was observed that the permeability of model diffusants decreased significantly with an increase in the connective tissue layer. However, the epithelium offered a stronger barrier to permeation of all diffusants studied at mucosal thickness of up to 500 |tm. The epithelium acted as a stronger barrier for hydrophilic diffusants when compared to lipophilic diffusants. It was also observed that the permeability of model diffusants was significantly higher in the region behind lip when compared to the middle cheek region which is due to lower epithelial thickness in that region. Porcine buccal mucosa retained its integrity in Kreb's bicarbonate Ringer solution at 4 °C for 24 hours and many other storage conditions resulted in loss of epithelial integrity. Separation of epithelium from the underlying connective tissue by heat treatment, did not adversely affect its permeability and integrity characteristics. Influence of experimental temperature on the permeability of model compounds across porcine buccal mucosa was also investigated in vitro. An exponential relationship was observed between the apparent permeability and temperature. It was found that the activation energy of diffusion of the model compounds decreased linearly with increasing distribution coefficients across porcine buccal mucosa. This suggested that the buccal mucosa acted as a stronger barrier for diffusion of hydrophilic diffusants when compared to the lipophilic diffusants.

Notre thèse de pharmacie clinique est une contribution à l'optimisation de l'efficience du traitement antirétroviral (TAR) par des méthodes de modélisation en Côte d'Ivoire. La première étude a été consacrée à une modélisation de la réponse antirétrovirale par taxonomie des trajectoires de taux de CD4 en utilisant un modèle de méta-apprentissage des trajectoires d'indicateurs biomédicaux. Ce modèle appliqué à la taxonomie des trajectoires des taux de CD4 a montré son intérêt dans la mise en évidence de classes distinctes de patients avec des caractéristiques particulières justifiant et/ou déterminant le profil particulier de méta-trajectoires de leur marqueur immunologique au cours du traitement. La deuxième tâche a consisté en une évaluation de l'impact de principaux déterminants des méta-trajectoires de taux de CD4 sur divers types de réponse immunologique à partir d'un modèle explicatif avec une équation de régression logistique. Les réponses immunologiques considérées ont été exprimées en termes d'absence de gain de CD4, de gain sub-optimal et de gain optimal de CD4 à différentes périodes de suivi du TAR. Enfin l'évaluation de l'efficience des stratégies antirétrovirales de première ligne en Côte d'Ivoire, a été abordée dans la dernière partie avec un modèle pharmaco-économique. Nous avons effectué une étude préliminaire ouvrant des perspectives pour encourager la mise en oeuvre d'évaluations pharmaco-économiques complètes par modélisation en Côte d'Ivoire. Elle a permis de mettre en exergue les parties méthodologiques pouvant être sujettes à caution dans une étude de modélisation pharmaco-économique des TAR de première ligne dans un contexte de ressources limitées

Dans l'épilepsie du globe temporal (ELT), l'hyperexcitabilité est attibuée à la mort neuronale, la gliose et la plasticité synaptique. Un remodelage vasculaire n'a jamais été recherché dans le tissu épileptique, bien que des données récentes suggèrent que la perméabilité de la barrière hémato-encéphalique (BHE) est épileptogène. Nous avons observé dans l'hippocampe de patients atteints d'ELT réfractaire une dégradation de la BHE, une néo-vascularisation et la surexpression du Vascular Endothelial Growth Factor (VEGF) et de son récepteur VEGFR-2. Pour comprendre cette angiogenèse, nous avons modélisé l'épilepsie in vivo et in vitro chez le rat. In vivo, la néo-vascularisation, la surexpression de VEGF/VEGFR-2 et la rupture de BHE sont présentes dans un modèle avec lésions et gliose, mais transitoires dans un modèle non lésionnel. In vitro, nous avons observé que des crises déclenchées sur des cultures organotypiques d'hippocampe (COHs) induisent une angiogenèse et une dégradation de BHE qui ne persiste qu'en présence de lésions. Nous avons étudié le rôle du VEGF in vitro, en le neutralisant ou en inhibant des voies de signalisation de VEGFR-2 dans les COHs, confirmant l'importance du PKC et src dans l'angiogenèse et la dégradation de la BHE. De plus, nous avons montré un déséquilibre des angiopoiétines en faveur d'Ang2 qui potentialise les effets du VEGF. Chez l'homme et l'animal, la rupture de la BHE persiste dans les foyers chroniques entretenant l'induction des crises. En ciblant des facteurs angiogéniques pour réparer la BHE, nous espérons réduire l'épileptogenèse et donc proposer de nouvelles stratégies pour les épilepsies réfractaires
In Temporal Lobe Epilepsy, hyper excitability is commonly attributed to neuronal loss, and synaptic plasticity in the hippocampus. A vascular remodeling has never been investigated in epileptic tissue, althought recent data indicate that blood brain barrier (BBB) permeability is epileptogenic. In the hippocampus of patients with intractable TLE, we observed vascular changes like BBB leakage, increased vascular density and over expression of Vascular Endothelial Growth Factor (VEGF) and its receptor VEGFR-2. To understand the mechanisms of this angiogenesis, we used in vivo and in vitro rat models of epilepsy. In vivo, we found neo-vascularization, over expression of VEGF/VEGFR-2 and BBB disruption in a model with neuronal loss and gliosis, whereas in a model without lesion these vascular changes were only transient. In vitro, we showed that seizures, generated in organotypic hippocampal cultures (OHCs), induce angiogenesis and BBB degradation which persist only in presence of lesions. We investigated in vitro the role of VEGF by neutralizing VEGF or inhibiting different VEGFR-2 signaling pathways in OHCs and confirmed the importance of PKC and src pathways in angiogenesis and BBB degradation. More, we observed a deregulation of angiopoietin ration in favor of Ang2, which increases VEGF effects. In humans and animals, angiogenesis and BBB disruption persist in the chronic focus, whereas BBB leakage is known to participate in seizure induction. Therefore, by targeting angiogenic factors, we aim at repairing the BBB and thus reducing epileptogenicity. This study could lead to the development of new therapies for intractable epilepsies

There is significant interest in the field of neuroscience to gain a better understanding of how neurons die in neurodegenerative diseases such as Alzheimer's and Parkinson's diseases. We have used the neuronal cell line NG115-401L with unique calcium signaling characteristics to test the hypothesis that improving calcium loading into the endoplasmic reticulum (ER) to increase ER calcium levels acts as a possible neuroprotective response. We approached this problem using both pharmacological and genetic approaches targeting the central mediator of calcium uptake in the ER localized sarco/endoplasmic reticulum Ca 2+ ATPase (SERCA) enzyme. The pharmacological studies involved use of the ginger root compound 6-gingerol, which to date is the best documented agent for activating SERCA enzymes in heart and skeletal muscle. However, in our experiments, gingerol did not appear to activate NG115-401L SERCA pumps; indeed, the compound produced a response more like that of a SERCA inhibitor inducing a rapid ER calcium depletion. In addition, gingerol stimulated robust calcium influx responses, an unexpected result given the NG115-401L neural cell line is uniquely deficient in calcium influx pathways. Our genetic approach involved expressing the stromal interaction molecule 1 (STIM1) protein in the NG115-401L cell, which is also an ER localized protein that serves as a pivotal calcium influx channel regulator. NG115-40lL neurons present a native deficiency of STIM1 expression in a background phenotype with well characterized perturbations in ER calcium regulation and control of calcium influx pathways. Thus, STIM1 may be predicted to increase ER calcium levels, conferring protection against neuron cell death due to ER calcium store defects. STIM1 expression reconstituted the corrupted calcium influx pathway in NG115-401L neurons, which conferred neuroprotective responses to ER calcium perturbation, mitochondrial oxidative stress and subsequent cell death. Our results argue for unique and undiscovered regulatory effects of gingerol on the ER calcium circulation system, and suggest that the expression of STIM1 in these neurons protects against ER stress and oxidative stress via reconstruction of cellular calcium homeostasis.

Dans la perspective de trouver de nouvelles thérapies dans le traitement du diabète de type II, non insulino-dépendant, le Glucagon-Like Peptide-1 (GLP-1) constitue un excellent candidat. Si son mécanisme d'action est bien connu, il reste toutefois à résoudre de grands problèmes fondamentaux, avant de le substituer aux molécules utilisées pour une telle pathologie. En particulier, la compréhension de la liaison du GLP-1 à son récepteur demeure un point crucial. Une meilleure connaissance des structures du ligand et du récepteur sont nécessaires. De plus, ce peptide ne peut être utilisé dans sa forme native, dû à une inactivation rapide par les protéases.

Pour essayer d'augmenter la stabilité du peptide, et en tenant compte des positions clés définies dans la littérature, plusieurs analogues du GLP-1-(7-37) sont conçus, et synthétisés. Ils possèdent principalement des pharmacomodulations au niveau de la partie N-terminale. Des substitutions sont également réalisées dans la partie centrale du peptide, permettant de vérifier certaines hypothèses concernant sa conformation. Considérant les résultats de liaison et d'efficacité in vitro, certains analogues sont sélectionnés pour des études in vivo d'activité et de stabilité métabolique. Le [a8,desR36]GLP-1-(7-37) se distingue des autres tant par sa grande stabilité que son efficacité, supérieure à la molécule native. Ce composé est en phase de développement pré-clinique.

Parallèlement, la conformation de chaque analogue est étudiée (CD, IR) et ainsi, confrontée aux résultats in vitro, il est possible de proposer une conformation bioactive.

Enfin, pour appréhender plus en avant les mécanismes de liaison du peptide avec son récepteur spécifique, la modélisation moléculaire du récepteur fait ressortir quelques hypothèses quant à la localisation probable de l'interaction hormone-récepteur. Des analyses biophysiques et la synthèse de fragments du récepteur, ont permis d'étayer de telles hypothèses.

Adsorption processes are utilized in both medicine and industry. It is important to have an understanding of adsorption processes to better predict the outcomes and discern potential difficulties. The primary objective of this research is to further the understanding of the nature and extent of the adsorption process in solution, which is a function of the chemical composition of the adsorbates, adsorbents, and solvent. This was accomplished by employing experimental studies as well as thermodynamic calculations and molecular dynamic simulations. Four activated carbons were used as the model adsorbents in this study. And, barbital, phenobarbital and primidone were used to elucidate the structural features of the adsorbates that were most responsible for the interaction with activated carbons. A Two-Mechanism Langmuir-Like Equation (TMLLE) was proposed to describe the independent presence of two adsorption mechanisms: non-site-specific adsorption and site-specific adsorption. The analyses of data generated by both previous investigators and current studies, suggest that the TMLLE allows an accurate analysis of the adsorption process. Based on the parameters in the TMLLE, the Modified Crisp Model and the van’t Hoff Model were employed to determine the Gibbs free energy changes for both site-specific adsorption and non-site-specific adsorption. Comparing the Gibbs free energy changes calculated by the Modified Crisp Model and the van’t Hoff Model (site-specific adsorption case), it is concluded that 5 water molecules are displaced by a phenobarbital molecule on the surface of activated carbons. And, for non-site-specific adsorption, it is concluded that 12 water molecules are displaced by a phenobarbital molecule on the nonpolar (hydrocarbon) part of the activated carbon surface. The adsorption of phenobarbital from solution by activated carbons has been simulated by employing Molecular Dynamic (MD) Modeling. The predicted differential Gibbs free energy values for site-specific adsorption at pH 2-9 were consistent with the thermodynamic calculations. And, the present MD simulations provide a good basis for the further understanding and quantitatively assessment of the adsorption driven by hydrophobic bonding. The conclusions reached in the current studies are expected to be applicable to a wide range of similar adsorption processes.

Opioid analgesics are commonly used to treat acute and chronic pain; in 2016 alone, more than 60 million patients had at least 1 prescription for opioid analgesics filled or refilled. Despite the ubiquitous use of these agents, the effectiveness of long-term use of opioids for chronic noncancer pain management is questionable, yet links among long-term use, addiction, and overdose deaths are well established. Because of overprescribing and misuse, an opioid epidemic has developed in the United States. The health and economic burdens of opioid abuse on individuals, their families, and society are substantial. Part 1 of this supplement will provide a background on the burden of pain and the impact of opioid abuse on individuals, their families, and society; the attempts to remedy this burden through prescription opioid use; and the eventual downward spiral into the current opioid epidemic, including an overview of opioid analgesics and opioid use disorder and the rise in opioid-related deaths

The elderly population is among the fastest growing populations in the United States. Finding and consuming medications safely and effectively are challenging endeavors for this population. Nonsteroidal anti-inflammatory drugs (NSAIDs) are a widely consumed class of medications among the elderly population, with 70% of individuals consuming over-the-counter (OTC) NSAIDs once a week and 34% using them daily. The purpose of this quantitative study was to determine whether (a) patients are aware of the risks associated with the consumption of NSAIDs, and (b) there are differences in awareness based upon specific demographic characteristics and levels of patient-physician communication. The health belief model (HBM) was used to interpret the results. The HBM is a social cognition framework that takes into account different perceptions, namely, perceived susceptibility of acquiring a health condition, perceived severity of the condition and its consequences, perceived barriers to engaging in the recommended behavior, perceived benefits of engaging in the recommended behavior, and perceived costs of engaging in the recommended behavior. Multiple linear regression was used to analyze the data. The results, which were based upon a cross-sectional survey of 124 participants, showed that the participants' awareness of adverse events associated with NSAIDs use was not associated with sociodemographic variables, rates of consumption, or patient-physician communication. The findings will give the key stakeholders more insight into the issue of preventable adverse events that might lead to the establishment of more safety programs and informatics structural systems to monitor the consumption of OTC NSAIDs and improve lines of communication to protect the elderly population.

The current project examined the ability of a novel series of guandine and amidine-containing nicotine analogs to interact with several native and recombinantlyexpressed mammalian neuronal nicotinic-acetylcholine receptor (nAChR) subtypes. Rational drug design methods and parallel organic synthesis was used to generate a library of guanidine-containing nicotine (NIC) analogs (AH compounds). A smaller series of amidine-containing nicotine analogs (JC compounds) were also synthesized. In total, >150 compounds were examined. Compounds were first assayed for affinity in a high-throughput [3H]epibatidine radioligand-binding screen. Lead compounds were evaluated in subtype-selective binding experiments to probe for affinity at the α4β2* and α7* neuronal nAChRs. Several compounds were identified which possess affinity and selectivity for the α4β2* subtype [AH-132 (Ki=27nm) and JC-3-9 (Ki=11nM)]. Schild analysis of binding suggests a complex one-site binding interaction at the desensitized high-affinity nAChR. Whole-cell functional fluorescence (FLIPR) assays revealed mixed subtype pharmacology. AH-compounds were identified which act as activators and inhibitors at nAChR subtypes, while lead JC-compounds were found which possess full agonist activity at α4β2* and α3β4* subtypes. Compounds were identified as partial agonists, full agonists and inhibitors of multiple nAChR subtypes. Several SAR-based, ligand-receptor pharmacophore models were developed to guide future ligand design. Second-generation lead compounds were identified.

Individuals born with primary immune deficiency diseases (PIDD) have a dysfunctional immune system, and many are treated by lifelong injections of immunoglobulin therapy. Studies have shown that these patients have low health-related quality of life (HRQOL) and well-being (WB) and that these outcomes might be improved by the availability of therapy innovated according to preferences for fewer needle sticks or a shorter infusion time. Regulators at the U.S. Food and Drug Administration (FDA) have approved therapies innovated per these preferences. However, there is limited data demonstrating how these innovations impact HRQOL and WB. Using the biopsychosocial model, the purpose of this cross sectional quantitative study was to evaluate whether patients with PIDD using therapies innovated for fewer needle sticks or a shorter infusion time had a higher mean HRQOL and WB compared to those who were not. The study included 153 patients who completed the Patient Reported Outcomes Measurement Information System (PROMIS)-29 survey. The dependent variables were HRQOL and WB measured by PROMIS-29, and the independent variables were the medical product innovations. Independent samples t tests results showed mean PROMIS-29 scores were not statistically different (p > .05). This suggests patients were optimized according to their treatment preference. A subgroup of patients who had taken the PROMIS-29 survey more than once concurrent with switching to a therapy aligned with patient preferences showed improved HRQOL and WB. These findings have implications for positive social change in that seeking the patient's voice to inform medical product innovation and FDA regulatory decision-making has potential to improve biopsychosocial outcomes.

Benzo[a]pyrene (BaP), is one of the most potent mutagens and carcinogens known. It requires metabolic activation through cytochrome P450 (CYP)1A1 to yield the ultimate carcinogenic metabolite, benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide (BPDE). BPDE can bind to DNA and form predominantly covalent (+) trans adducts at the N2 position of guanine causing DNA damage. Rutaecarpine (RTC) is an herbal medicine that has been used to treat several diseases such as headache, hypertension, gastrointestinal disorders, amenorrhea, and anti-inflammation. It has also been reported as a potent inducer of CYP enzymes, including CYP1A1, and CYP1A2. The mechanisms underlying up-regulation of CYP1A1 by RTC is dependent on aryl hydrocarbon receptors. Meanwhile, RTC can inhibit the activity of CYP1A1, CYP1A2 and CYP1B1. To investigate the effect of RTC on the BaP-induced DNA damage, we analyzed the CYP1A1 enzyme activity and DNA damage level in two cell lines, namely mucoepidermoid pulmonary carcinoma cells (H292) and hepatocellular carcinoma cells (Hep3B). The cells either were treated with only 5 μM BaP or 1.25, 2.5, 5 and 10 μM RTC, respectively; or were co-administrated 5 μM BaP and one of the four concentrations of RTC for 24 hours. Ethoxyresorufin-O-deethylase (EROD) assay was used to detect CYP1A1 enzyme activity. The results showed that both BaP and RTC significantly (p<0.05) induced CYP1A1 enzyme activity when administered separately, with RTC induction exhibiting a concentration-dependent manner. Interestingly, co-administration of RTC with BaP, especially at high concentration (10 μM) of RTC, induced less CYP1A1 enzyme activity compared to either only RTC or BaP administration. MuseTM Multi-Color DNA Damage kit was used to evaluate the DNA damage level in cells. The data showed that the DNA damage induced by BaP alone was about 2-fold higher (p&;lt;0.05) than that by concurrent administration of RTC and BaP. In conclusion, our data showed that although both RTC and BaP are inducers of CYP1A1 enzyme, their co-administration will reduce CYP1A1 enzyme activity compared with BaP administration alone. The DNA damage kit results supported that there is a potential protective effect of RTC against BaP-induced DNA damage in both H292 and Hep3B cells.

Contexte : Les neuroleptiques sont souvent prescrits chez les sujets âgés et les patients souffrant de schizophrénie qui sont des personnes vulnérables. Notre objectif était d'étudier l'impact des NLP en situation réelle de prescription, dans ces deux populations. Etude 1. Consommation de neuroleptiques et décès en période de canicule chez les sujets âgés. A partir de données de l'Assurance Maladie, nous avons comparé les prescriptions de NLP chez des sujets âgés décédés pendant la canicule d'août 2003 (n=11624) aux prescriptions de témoins non décédés. Nous avons mis en évidence une association entre risque de décès et consommation de neuroleptiques, que ce soit juste avant ou pendant le pic de canicule et indépendamment d'autres médicaments, d'une démence ou d'une pathologie cardiaque. Etude 2. Efficacité réelle des NLP chez les patients souffrant de schizophrénie. A partir de données d'une cohorte observationnelle ayant inclus en France entière des schizophrènes adultes, nous avons montré que chez les patients déjà traités par NLP (n=5500), il y avait une association entre traitement par antipsychotique atypique (vs. NLP classique) et une meilleure satisfaction avec les soins et ce, pour tous les AA pris en compte et indépendamment du niveau de symptomatologie. Par ailleurs, chez les patients naïfs vis-à-vis de tout NLP et pour qui un traitement était introduit pour la première fois (n=467), un tiers des patients ne s'améliorait pas. Les facteurs prédictifs d'une meilleure réponse clinique étaient une moindre sévérité initiale globale des symptômes et des symptômes négatifs de schizophrénie. Au total, il existait cinq types de trajectoires d'évolution clinique.

Le système de reconnaissance du partenaire sexuel (SMRS) développé par Paterson est un critère important dans la caractérisation des espèces. Dans ce cadre, l'étude d'un complexe d'espèces de Lépidoptères trouve son intérêt. Au Kenya, le genre Busseola est représenté par trois espèces. B. fusca offre un cas intéressant de passage quasi absolu du compartiment sauvage au compartiment cultivé ; B. phaia et B. segeta s'apparentent à un cas de fidélité à l'hôte endémique. B. phaia et B. segeta partagent leurs aires de répartition avec B. fusca, mais sont isolées par la vallée du Rift et par les plantes-hôtes. B. segeta et B. phaia montre une grande proximité systématique. Nous avons étudier ces taxa au travers d'une approche d'écologie chimique et de phylogénie. La diversité génétique observée chez B. fusca au niveau populationnel n'est pas corrélée avec une variabilité du SMRS. Chez B. phaia et B. segeta, l'étude du SMRS a permis de caractériser les composantes de l'isolement reproducteur. L'analyse phylogénétique combinée à l'écologie chimique a permis d'émettre différentes hypothèses quant au statut d'espèce de B. phaia et B. segeta.

Dans l'épilepsie du lobe temporal (ELT), l'hyperexcitabilité est attribuée à la mort neuronale, la gliose et la plasticité synaptique. Un remodelage vasculaire n'a jamais été recherché dans le tissu épileptique, bien que des données récentes suggèrent que la perméabilité de la barrière hémato-encéphalique (BHE) est épileptogène.
Nous avons observé dans l'hippocampe de patients atteints d'ELT réfractaire une dégradation de la BHE, une néo-vascularisation et la surexpression du vascular endothelial growth factor (VEGF) et de son récepteur VEGFR-2.
Pour comprendre cette angiogenèse, nous avons modélisé l'épilepsie in vivo et in vitro chez le rat. In vivo, la néo-vascularisation, la surexpression de VEGF/VEGFR-2 et la rupture de BHE sont présentes dans un modèle avec lésions et gliose, mais transitoires dans un modèle non lésionnel.
In vitro, nous avons observé que des crises déclenchées sur des cultures organotypiques d'hippocampe (COHs) induisent une angiogenèse et une dégradation de BHE qui ne persiste qu'en présence de lésions.
Nous avons étudié le rôle du VEGF in vitro, en le neutralisant ou en inhibant des voies de signalisation de VEGFR-2 dans les COHs, confirmant l'importance de PKC et src dans l'angiogenèse et la dégradation de la BHE. De plus, nous avons montré un déséquilibre des angiopoiétines en faveur d'Ang2 qui potentialise les effets du VEGF.
Chez l'homme et l'animal, la rupture de la BHE persiste dans les foyers chroniques entretenant l'induction des crises. En ciblant des facteurs angiogéniques pour réparer la BHE, nous espérons réduire l'épileptogenèse et donc proposer de nouvelles stratégies pour les épilepsies réfractaires.

L'iatrogénie médicamenteuse à l'hôpital est un problème majeur de santé publique dont les causes sont multiples. La diffusion de recommandations de bonnes pratiques de prescription pourrait permettre de diminuer ce phénomène. L'objectif de cette thèse est de modéliser un vecteur possible des bonnes pratiques de prescription, celui des interventions pharmaceutiques. Ce travail se décline en trois séquences : 1.contexte et justification, 2.développement d'un outil de documentation et d'analyse des interventions pharmaceutiques, 3.évaluation d'un modèle de diffusion des recommandations associant l'intervention d'un pharmacien clinicien intégré dans l'unité de soins à un rappel informatique de l'intervention au moment de la prescription. L'ensemble de ces données assoit la pertinence d'une diffusion des interventions pharmaceutiques basée sur les outils technologiques et les activités de pharmacie clinique.

La recherche scientifique vise à produire des connaissances objectives, tandis que l'éthique s'intéresse à la réalisation des valeurs. Malgré l'éloignement de ces deux domaines, cette thèse vise à montrer de quelle façon sciences et valeurs se forment et s'informent mutuellement.
Ce travail s'appuie sur une étude de cas, celui de la constitution de fichiers de données à caractère personnel par les épidémiologistes, et vise à éclaire les problèmes éthiques et épidémiologiques que suscitent ces fichiers. Une approche historique permet de retracer l'émergence en France de la loi du 1er juillet 1994 qui encadre – c'est-à-dire à la fois permet et contraint – de telles pratiques à finalité scientifique. Les notions directrices du questionnement éthique sur la recherche avec l'être humain (mesures invasives, respect des personnes, consentement, respect du secret médical) sont alors retravaillées sous un jour nouveau.
L'épidémiologie est une science située à mi-chemin entre clinique et santé publique, entre action et recherche, et elle se révèle profondément hétérogène dans ses pratiques. Une approche de terrain, centrée sur l'activité évaluatrice du Comité Consultatif sur le Traitement de l'Information en matière de Recherche dans le Domaine de la Santé (CCTIRS), a permis d'analyser les normes de qualité scientifique en ce domaine.
Questionner philosophiquement la mise à l'épreuve de la scientificité de l'épidémiologie dans le cadre des normes de confidentialité conduit (1) à raviver le problème de la démarcation science/non-science et (2) à souligner le rôle que certaines valeurs constitutives de l'intentionnalité scientifique ont à jouer dans le partage entre l'authentique et l'inauthentique en matière de recherche.

碩士
嘉南藥理大學
環境資源管理系
107
In this study, we compared the electricity generated by renewable energy and the power consumed in a smart greenhouse on the campus of Chia Nan University of Pharmacy and Science. With the occupied area about 120m2, the facility mainly includes a treated sewage polishing system to recycle the wastewater for irrigation, and a vegetation system comprised of hypotonic and soil cultivation for different vegetation. An IoT (Internet of Things) based smart system for both online monitoring and control includes water quality, irrigation, indoor and outdoor environment, and power production and consumption. The energy budget analysis between both city electrical grid and solar panel units (HISG and CIGS) showed that the total electricity consumption in the facility was around two folds higher than production, which were 4,742.6 vs. 2,568.3 kWh from March, 2018 to June, 2019. The monthly electricity consumption in the facility ranged from 66.35~242.18 kWh with the highest in May, 2018. In general, electricity generated from solar panels increased in the hotter months from 32.07 kWh in Feb, 2019 to 242.18 kWh in May, 2018. Further analysis of the data also indicated that HISG was more efficient than CIGS with 20~35% differences in efficiency.

Les nanotechnologies appliquées aux sciences pharmaceutiques ont pour but d’améliorer l’administration de molécules actives par l’intermédiaire de transporteurs nanométriques. Parmi les différents types de véhicules proposés pour atteindre ce but, on retrouve les nanoparticules polymériques (NP) constituées de copolymères “en bloc”. Ces copolymères permettent à la fois l’encapsulation de molécules actives et confèrent à la particule certaines propriétés de surface (dont l’hydrophilicité) nécessaires à ses interactions avec les milieux biologiques. L’architecture retenue pour ces copolymères est une structure constituée le plus fréquemment de blocs hydrophiles de poly(éthylène glycol) (PEG) associés de façon linéaire à des blocs hydrophobes de type polyesters. Le PEG est le polymère de choix pour conférer une couronne hydrophile aux NPs et son l’efficacité est directement liée à son organisation et sa densité de surface. Néanmoins, malgré les succès limités en clinique de ces copolymères linéaires, peu de travaux se sont attardés à explorer les effets sur la structure des NPs d’architectures alternatives, tels que les copolymères en peigne ou en brosse. Durant ce travail, plusieurs stratégies ont été mises au point pour la synthèse de copolymères en peigne, possédant un squelette polymérique polyesters-co-éther et des chaines de PEG liées sur les groupes pendants disponibles (groupement hydroxyle ou alcyne). Dans la première partie de ce travail, des réactions d’estérification par acylation et de couplage sur des groupes pendants alcool ont permis le greffage de chaîne de PEG. Cette méthode génère des copolymères en peigne (PEG-g-PLA) possédant de 5 à 50% en poids de PEG, en faisant varier le nombre de chaînes branchées sur un squelette de poly(lactique) (PLA). Les propriétés structurales des NPs produites ont été étudiées par DLS, mesure de charge et MET. Une transition critique se situant autour de 15% de PEG (poids/poids) est observée avec un changement de morphologie, d’une particule solide à une particule molle (“nanoagrégat polymére”). La méthode de greffage ainsi que l’addition probable de chaine de PEG en bout de chaîne principale semblent également avoir un rôle dans les changements observés. L’organisation des chaînes de PEG-g-PLA à la surface a été étudiée par RMN et XPS, méthodes permettant de quantifier la densité de surface en chaînes de PEG. Ainsi deux propriétés clés que sont la résistance à l’agrégation en conditions saline ainsi que la résistance à la liaison aux protéines (étudiée par isothermes d’adsorption et microcalorimétrie) ont été reliées à la densité de surface de PEG et à l’architecture des polymères. Dans une seconde partie de ce travail, le greffage des chaînes de PEG a été réalisé de façon directe par cyclo-adition catalysée par le cuivre de mPEG-N3 sur les groupes pendants alcyne. Cette nouvelle stratégie a été pensée dans le but de comprendre la contribution possible des chaines de PEG greffées à l’extrémité de la chaine de PLA. Cette librairie de PEG-g-PLA, en plus d’être composée de PEG-g-PLA avec différentes densités de greffage, comporte des PEG-g-PLA avec des PEG de différent poids moléculaire (750, 2000 et 5000). Les chaines de PEG sont seulement greffées sur les groupes pendants. Les NPs ont été produites par différentes méthodes de nanoprécipitation, incluant la nanoprécipitation « flash » et une méthode en microfluidique. Plusieurs variables de formulation telles que la concentration du polymère et la vitesse de mélange ont été étudiées afin d’observer leur effet sur les caractéristiques structurales et de surface des NPs. Les tailles et les potentiels de charges sont peu affectés par le contenu en PEG (% poids/poids) et la longueur des chaînes de PEG. Les images de MET montrent des objets sphériques solides et l'on n’observe pas d’objets de type agrégat polymériques, malgré des contenus en PEG comparable à la première bibliothèque de polymère. Une explication possible est l’absence sur ces copolymères en peigne de chaine de PEG greffée en bout de la chaîne principale. Comme attendu, les tailles diminuent avec la concentration du polymère dans la phase organique et avec la diminution du temps de mélange des deux phases, pour les différentes méthodes de préparation. Finalement, la densité de surface des chaînes de PEG a été quantifiée par RMN du proton et XPS et ne dépendent pas de la méthode de préparation. Dans la troisième partie de ce travail, nous avons étudié le rôle de l’architecture du polymère sur les propriétés d’encapsulation et de libération de la curcumine. La curcumine a été choisie comme modèle dans le but de développer une plateforme de livraison de molécules actives pour traiter les maladies du système nerveux central impliquant le stress oxydatif. Les NPs chargées en curcumine, montrent la même transition de taille et de morphologie lorsque le contenu en PEG dépasse 15% (poids/poids). Le taux de chargement en molécule active, l’efficacité de changement et les cinétiques de libérations ainsi que les coefficients de diffusion de la curcumine montrent une dépendance à l’architecture des polymères. Les NPs ne présentent pas de toxicité et n’induisent pas de stress oxydatif lorsque testés in vitro sur une lignée cellulaire neuronale. En revanche, les NPs chargées en curcumine préviennent le stress oxydatif induit dans ces cellules neuronales. La magnitude de cet effet est reliée à l’architecture du polymère et à l’organisation de la NP. En résumé, ce travail a permis de mettre en évidence quelques propriétés intéressantes des copolymères en peigne et la relation intime entre l’architecture des polymères et les propriétés physico-chimiques des NPs. De plus les résultats obtenus permettent de proposer de nouvelles approches pour le design des nanotransporteurs polymériques de molécules actives.
The goal set to nanotechnologies applied to pharmaceutical sciences is to improve drug delivery and benefits with the help of nanometer-sized vehicles. At this time different types of drug carriers had been proposed. Amongst them, block copolymer nanoparticles (NP) have been designed to allow, at the same time, efficient drug encapsulation and provide surface properties (hydrophilic layer) to the NP which are necessary for its interactions with biological systems by preventing the opsonisation and the subsequent recognition by the mononuclear macrophage system (MPS) and the rapid elimination of the drug carrier. The most prominent polymer architecture in drug delivery application is the linear di-block copolymer architecture, such as poly(ethylene glycol) blocks (PEG) linked to a polyester hydrophobic chain. PEG is the gold standard to add a hydrophilic corona to drug carrier’s surface, but its efficacy is directly linked to its surface organization and surface densities. In spite of limited success of diblock at the clinical stage, few studies have been devoted to other type of architecture such as comb-like copolymers, either for the exploration of new synthesis routes or for the characterization of particles prepared from alternative architecture polymers. We attempted in preamble of this work to define more closely the conceptual and technical framework allowing quantitative determination of PEG surface densities. This review work has been used in the experimental work to define the characterization methods. Several synthesis strategies have been developed for the preparation of comb copolymers in this work. All strategies are based on random copolymerization of dilactide with small epoxy molecules with a pendant group suitable for subsequent PEG grafting, yielding a polyester-co-ether backbone. In a second step, PEG chains have been grafted on available pendant groups (alcohol groups or alkyne) to produce the final comb copolymers. In the first part of the experimental work, esterification reaction by acylation and coupling (the Steglish reaction) allowed the preparation of a first comb-like copolymer library with PEG content varying from 5 to 50 % (w/w). The number of PEG chains (PEG grafting density) was varying while the lengths of the PEG chains and the hydrophobic PLA backbone were kept constant. The library of comb-like polymers was used to prepare nanocarriers with dense PEG brushes at their surface, stability in suspension, and resistance to protein adsorption. The structural properties of nanoparticles (NPs) produced from these polymers by a surfactant-free method were assessed by DLS, zeta potential, and TEM and were found to be controlled by the amount of PEG present in the polymers. A critical transition from a solid NP structure to a soft particle with either a “micelle-like” or “polymer nano-aggregate” structure was observed when the PEG content was between 15 to 25% w/w. This structural transition was found to have a profound impact on the size of the NPs, their surface charge, their stability in suspension in presence of salts as well as on the binding of proteins to the surface of the NPs. The arrangement of the PEG-g-PLA chains at the surface of the NPs was investigated by 1H NMR and X-ray photoelectron spectroscopy (XPS). NMR results confirmed that the PEG chains were mostly segregated at the NP surface. Moreover, XPS and NMR allowed the quantification of the PEG chain coverage density at the surface of the solid NPs. Concordance of the results between the two methods was found to be remarkable. Physical-chemical properties of the NPs such as resistance to aggregation in saline environment as well as anti-fouling efficacy, assessed by isothermal titration calorimetry (ITC), were related to the PEG surface density and ultimately to polymer architecture. In the second part of this work, grafting of PEG chains on a polyester-co-ether backbone was directly performed using cyclo-addition of PEG azide on pendant alkyne groups. The new strategy was designed to understand the contribution of PEG chains grafted on PLA backbone ends. The new polymer library was composed of PEG-g-PLA with different PEG grafting densities and PEG molecular weights (750, 2000 and 5000 D). PEG chain grafting could only take place on pendant groups with this approach. NPs were produced by different methods of nanoprecipitation, including “flash nanoprecipitation” and microfluidic technology. Some formulation variables such as polymer concentration and speed of mixing were studied in order to observe their effects on NP surface characteristics. Unlike for the first copolymer library, here the NPs size and zeta potential were found to not be much affected by the PEG content (% w/w in polymer). Sizes were also not affected by the PEG chains length. TEM images show round shaped object and as expected sizes were found to decrease with polymer concentration in the organic phase and with a decrease in mixing time of the two phases (for flash nanoprecipitation and microfluidic technology). PEG chain surface densities were assessed by quantitative 1H NMR and XPS. In the third experimental part, we explored the role of polymer architecture on drug encapsulation and release of curcumin from NPs. Curcumin has been chosen as a model with a view to develop a delivery platform to treat diseases involving oxidative stress affecting the CNS. As previously observed with blank NPs, a sharp decrease in curcumin-loaded NP size and morphology change occurred between 15 to 20 % w/w of PEG. Drug loading, Drug loading efficiency and the diffusion coefficients of curcumin in NPs are showing a dependence over the polymer architecture. NPs did not present any significant toxicity when tested in vitro on a neuronal cell line. Moreover, the ability of NPs carrying curcumin to prevent oxidative stress was evidenced and linked to polymer architecture and NPs organization. In a nutshell, our study showed the intimate relationship between the polymer architecture and the biophysical properties of the resulting NPs and sheds light on new approaches to design efficient NP-based drug carriers. The results obtained lead us to propose PEG-g-PLA comb architecture copolymers for nanomedecine development as an alternative to the predominant polyester-PEG diblock polymers.

La barrière hémato-encéphalique (BHE) est une structure retrouvée au niveau des capillaires cérébraux. Elle représente un véritable obstacle pour les actifs qui doivent se rendre au cerveau pour y exercer un effet pharmacologique. Durant les étapes du développement du médicament, des modèles cellulaires in vitro sont utilisés pour l’évaluation de la perméabilité au cerveau des nouveaux médicaments. Le modèle assemblé avec des cellules endothéliales (CEs) isolées des capillaires des cerveaux de souris présente un intérêt particulier pour la recherche en raison de sa facilité d’obtention et sa pertinence pour le criblage des médicaments. Le but de ce projet a été de construire et de caractériser un modèle monocouche de CEs primaires de souris. En parallèle, un modèle monocouche de la lignée murine b.End3 a été investigué. L’évaluation de ces modèles a été basée sur les valeurs de TEER et de perméabilité aux marqueurs fluorescents, ainsi que sur la présence des protéines spécifiques de la BHE. La validation du modèle a été établie par la corrélation des résultats de perméabilité obtenus avec le modèle développé (in vitro) avec ceux obtenus chez la souris (in vivo). L’intégrité et l’expression des protéines spécifiques de la BHE du modèle primaire se sont montrées supérieures au modèle bEnd.3. La corrélation in vitro/in vivo du modèle primaire a abouti à un r2 = 0,765 comparé au r2 = 0,019 pour le modèle bEnd.3. Ce travail de recherche montre que le modèle primaire monocouche issu de cellules endothéliales cérébrales de souris est un modèle simple et fiable pour la prédiction de la perméabilité des actifs à travers la BHE.
The blood-brain barrier (BBB), a central nervous system structure, is found in the cerebral capillaries. It represents a major obstacle for the drugs that have to reach the brain in order to exercise their pharmacological effect. In the early stages of the drug development, in vitro cell models are used to evaluate the brain permeability of new drugs. Models assembled using primary endothelial cells (ECs) isolated from mouse brain capillaries are of particular interest for research, as for their ease of obtaining and relevance for the drug screening. Thus, the goal of this project was to build and characterize a primary mouse monolayer model. At the same time, a murine b.End3 cell line monolayer model was investigated. The evaluation of these models was based on the TEER and fluorescent marker permeability values, as well as on the presence of the BBB hallmark proteins. The model validation was established by the correlation of the permeability data obtained with the in vitro model and the data obtained in mice (in vivo). As a result, the primary mouse model showed superior monolayer integrity and higher expression of the tight junction and membrane transporter proteins when compared with the bEnd.3 cell line model. The in vitro/in vivo correlation of the primary model resulted in r2 = 0.765 compared to the bEnd.3 model with r2 = 0.019. This research work shows that the primary monolayer mouse model is a simple and reliable model for predicting the drug permeability across the BBB.